Entering text into the input field will update the search result below

Aurinia completes enrollment of AURORA for the treatment of Lupus Nephritis

Sep. 26, 2018 7:45 AM ETAurinia Pharmaceuticals Inc. (AUPH) StockBy: Gaurav Batavia, SA News Editor8 Comments
  • Aurinia Pharmaceuticals (NASDAQ:AUPH) completed targeted enrollment of 324 patients for the AURORA Phase 3 trial ahead of schedule due to high patient demand with 358 lupus nephritis patients randomized in sites across 27 countries.
  • The AURORA clinical trial is a global, double-blind, placebo-controlled study to evaluate whether voclosporin when added to background therapy of mycophenolate mofetil/CellCept® can increase speed of and overall renal response rates in the presence of low dose steroids.
  • The primary endpoint for the study is complete renal response at 52 weeks, after which patients can choose to enroll into a 104-week blinded extension study.
  • “We look forward to sharing the results of the trial in late Q4 2019 and to completing our NDA submission in Q2 2020,” said Neil Solomons, M.D., Aurinia’s Chief Medical Officer.
  • Shares +3%
  • Press Release

Recommended For You

About AUPH Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AUPH--
Aurinia Pharmaceuticals Inc.